eGFR 48 mL/min/1.73 m²
An eGFR of 48 mL/min/1.73 m² corresponds to CKD G3a (mild to moderately decreased kidney function) if confirmed as chronic. [1] Chronic kidney disease is diagnosed when kidney function and/or markers of kidney damage persist for ≥3 months. [2]
Interpretation and staging
CKD G3a is defined as an eGFR of 45–59 mL/min/1.73 m². [1] CKD staging in KDIGO 2024 also uses albuminuria category based on urine ACR. [1] If GFR is reduced and/or albuminuria is present after ≥3 months, staging and risk stratification should be completed using both eGFR and urine ACR. [2]
Confirming chronicity and establishing cause
Serum creatinine-based eGFR should be repeated to confirm persistence for ≥3 months. [2] Urine albumin assessment with ACR is recommended for staging and risk. [2] The underlying cause of CKD should be established using clinical history, medication review, examination, laboratory tests, and imaging as indicated. [2] If the decrease in eGFR is severe or rapidly progressive, reassessment should occur earlier than the usual ≥3-month interval. [2]
Core management goals
Management should focus on delaying CKD progression and reducing cardiovascular risk. [2] Blood pressure control, treatment of albuminuria, and use of kidney-protective agents when indicated are central components of progression delay. [2] Monitoring should include GFR and albuminuria to update staging, estimate risk, and assess treatment effectiveness. [3]
Medication selection algorithm
Renin-angiotensin system inhibitors (RASi) include ACE inhibitors and ARBs. [4] RASi initiation is recommended for CKD with severely increased albuminuria (G1–G4, A3) without diabetes (Class 1B). [4] RASi initiation is suggested for CKD with moderately increased albuminuria (G1–G4, A2) without diabetes (Class 2C). [4] RASi initiation is recommended for CKD with moderately-to-severely increased albuminuria (G1–G4, A2 and A3) with diabetes (Class 1B). [4] ACE inhibitor and ARB combination therapy is recommended to be avoided (Class 1B). [4] SGLT2 inhibitors are recommended for adults with CKD with eGFR ≥20 mL/min/1.73 m² (Class 1A) when urine ACR is ≥200 mg/g (or when heart failure is present irrespective of albuminuria). [5] SGLT2 inhibitor use is suggested for adults with CKD with eGFR 20 to 45 mL/min/1.73 m² and urine ACR <200 mg/g (Class 2B). [5]
RASi monitoring and continuation
Monitoring of BP, serum creatinine, and serum potassium should be performed within 2–4 weeks of RASi initiation or dose increase. [4] ACE inhibitor or ARB therapy should generally be continued unless serum creatinine rises by >30% within 4 weeks of initiation or dose increase. [4] RASi is continued even if eGFR falls below 30 mL/min/1.73 m². [4]
Initiation thresholds relevant to eGFR 48
Urine ACR is required to apply the albuminuria-based medication recommendations for G3a. [2] SGLT2 inhibitor initiation commonly depends on albuminuria and clinical context because CKD with eGFR ≥20 mL/min/1.73 m² plus urine ACR ≥200 mg/g meets a Class 1A recommendation. [5] SGLT2 inhibitor initiation with eGFR 20 to 45 mL/min/1.73 m² and urine ACR <200 mg/g meets a Class 2B recommendation. [5]
Common pitfalls to avoid
CKD patients should be more susceptible to nephrotoxic medication effects, so potential harms should be weighed when such drugs are prescribed. [6] Approximately 18%–20% of people with CKD G3–G5 receive at least one potentially inappropriate nephrotoxic medication annually, primarily NSAIDs. [6] When medications with nephrotoxic potential are used, alternatives should be prioritized when possible. [6] A substantial early eGFR “dip” after starting kidney-protective therapies can occur and typically should prompt evaluation and close monitoring rather than automatic discontinuation. [3]
Targets and follow-up
GFR and urine ACR should be assessed at least annually in people with CKD. [3] GFR and albuminuria should be assessed more often when measurement will change therapeutic decisions or when the risk of progression is higher. [3]
Medication and lifestyle elements that affect progression risk
Physical inactivity should be avoided in CKD. [3] Dietary protein intake should generally be limited to avoid excess protein in adults with CKD at risk of progression (>1.3 g/kg body weight/day). [7]
Clinical actions to take with eGFR 48 mL/min/1.73 m²
Repeat eGFR and obtain urine ACR to confirm chronicity and complete CKD staging. [2] Assess and document the etiology of CKD using history, medications, labs, and imaging as indicated. [2] Use albuminuria-guided kidney-protective therapy with RASi and SGLT2 inhibitors when criteria are met. [4][5] Avoid or minimize nephrotoxic medications when possible, particularly NSAIDs. [6] Monitor GFR and urine ACR at least annually and adjust frequency based on progression risk and treatment changes. [3]